Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Segal Trials, founded in 1998, is a privately held network of seven research sites throughout South Florida conducting Phase I-IV research trials with a primary emphasis on psychiatry, neurology, addiction, insomnia, general medicine, healthy volunteers, infectious diseases, vaccines, and women’s health. Staying true to its core values of quality, customer service, advocacy, and patient care, the Segal Trials team of over 110 professionals remains agile and competitive, expanding and growing based on the needs of its sponsors and its patients. Federal law requires that every medication must go through a series of clinical research trials before being approved by the FDA, in addition to being approved by an independent Research Ethics Board. Clinical research trials are critical in the advancement of medicine and making available new and helpful medications. It is Segal Trials’ mission to play an integral role in the advancement process and help millions of people suffering from diseases.
Cellics Therapeutics, Inc. is a biotech company using the innovative Cellular Nanosponge platform technology to create treatment and vaccines for hard-to-treat infectious and inflammatory diseases. Cellics has a rich pipeline and its lead indication is ready to move into clinical phase 1b/2a. Cellics team is currently expanding quickly and we are looking for innovative and goal-driven team members to join the team.
Elsie’s technology relies on a three dimensional platform that allows for the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. Our hope to leverage an out of the box way of thinking as well as a multidisciplinary approach to bring safer and more efficacious therapeutics to the market to treat the most intractable human diseases.
BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.
CoreRx, Inc. is an industry leading Contract Development and Manufacturing Organization (CDMO), providing innovative drug formulation development, GMP manufacturing and packaging solutions to global pharmaceutical and bio-pharmaceutical partners. From its state-of-the-art, multi-site campus in Clearwater, Florida and its early product development center of excellence in San Rafael, California, CoreRx delivers value-added solutions to its partners, from clinic to commercial scale and across a range of dosage forms.
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. We use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic solutions that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery. LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on advancing highly impactful precision medicines in oncology and immune modulation. The Company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou.
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
Sepax Technologies, Inc., is Delaware based leading chromatography product manufacturer and service provider specializing in biological separation areas. We offer unique ranges of HPLC columns for bioanalytical characterization and testing, as well as process media for downstream process and purification of MAb, BsAb, ADC, Proteins, AAV, VLP, DNA, RNA, and various biologic samples. Sepax has a full portfolio of beads technology platforms, linker and organic synthesis chemistry, as well protein chemistry in different stages of R&D and production pipelines to support the various needs of biopharmaceutical industry and customers. Check out our website for more information www.sepax-tech.com
Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In 2022, Hound Labs will launch its first ultra-sensitive point-of-care solution – the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis use rapidly and accurately by testing breath on-site. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.
Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT’s goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today’s therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT’s proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development. Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
About Enzyvant Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare disease, where communities are small, and the human need is immense. Enzyvant partners with these communities to accelerate development of transformative medicines, collaborating with academia, industry, physician associations, advocacy groups and government, because strong relationships make bold science possible. Enzyvant has capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing. The company delivered one of the first Regenerative Medicine Advanced Therapy products and makes promising advances against some of the greatest challenges in immunology and cardiopulmonology. For more information about Enzyvant, visit www.Enzyvant.com.
Helix is a value-based, state-of-the-art clinical laboratory on a mission to elevate the lab space through compliance, high ethics, innovation and a best in class client experience. Helix incorporates the latest technology and methods to provide comprehensive diagnostics including toxicology testing, pathogen detection, blood testing and Pharmacogenomics (PGx) testing. We also provide drive up COVID-19 testing.
I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology. The company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong, and in Gaithersburg, Maryland, and San Diego, California.
Ichor Life Sciences is a premium pre-clinical contract research organization offering services in discovery through pharmacology. The company operates R&D laboratories in LaFayette and Potsdam, New York, including an AAALAC accredited vivarium. Services are provided through two divisions. Ichor Discovery Services provides world-class protein manufacturing, as well as a full suite of capabilities in structural biology, biophysics and assay development. Ichor Pharmacology Services offers in vitro testing, histology, PK/PD, in vivo toxicology and in vivo efficacy capabilities. Therapeutic areas served by Ichor Life Sciences include oncology, metabolic disease, musculoskeletal disease, ophthalmology, and geriatrics. Ichor Life Sciences was founded in 2013 and is headquartered in New York’s Finger Lakes intellectual corridor.
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, helping people live longer, healthier lives.
OneSkin is a longevity company on a mission to transform the way we think about skin and aging. Founded by a team of four female PhDs, OneSkin’s products aim to extend skinspan, the period of time skin is healthy and functional. OneSkin’s proprietary peptide, OS-01, is the first ingredient designed to reduce skin's biological age by improving skin barrier, supporting DNA damage repair, and preventing the accumulation of aged cells.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
